Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cardiology Advisor
The Heart Failure Society of America released a scientific statement establishing diagnostic criteria and a treatment framework for heart failure with mildly reduced ejection fraction, a phenotypically heterogeneous group historically underrepresented in dedicated interventional trials.
Cardiology June 2nd 2026
Medical News Today (MNT)
Daily peppermint oil supplementation was associated with reduced systolic blood pressure and resting heart rate in a small placebo-controlled trial of adults with elevated or stage 1 hypertension.
Medical Professionals Reference (MPR)
Lerochol (lerodalcibep-liga), a once-monthly self-administered PCSK9 inhibitor, is now commercially available as adjunctive LDL-C-lowering therapy for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
Cardiology May 19th 2026
Annals of Internal Medicine
A single-institution case series of 13 biopsy-proven hydroxychloroquine cardiomyopathy patients documented variable outcomes after drug cessation, ranging from full functional recovery to progression requiring advanced heart failure therapies.
MDSpire News
A Swedish national cohort analysis linked bereavement to elevated incident cardiovascular disease risk before and during the COVID-19 pandemic, with the strongest pandemic-period association following partner loss.
MDLinx
First-line pulsed field catheter ablation outperformed antiarrhythmic drug therapy for rhythm control at one year in patients with persistent atrial fibrillation, with similar serious adverse event rates.